Experts Share Insights on Evolving Global Vaccine Landscape Including mRNA Trends
Retrieved on:
금요일, 3월 3, 2023
Research, European, Mater Group, NEXT Woman of the Year awards, Royal college, Australasian, University of the Philippines Manila, Consultant, Senior, Editor-in-chief, Toxicology, IND, Protein, University, Royal Australasian College, Infection, COVID-19, ChromeOS, Marie Cassidy, Associate, Acquisition, Tropical medicine, Principal, Vaccine, Clinical trial, IVI, Drug development, Pharmacist, International Vaccine Institute, Licensure, SOP, Drug Development and Industrial Pharmacy, Medical microbiology, SK, Babaji, Pharmaceutical industry, Fine chemical, Pharmacology, Physician, Medicine
Babaji has a strong background in pharmaceutical sciences with a Ph.D. in Pharmacology and Toxicology from the University of Otago, New Zealand.
Key Points:
- Babaji has a strong background in pharmaceutical sciences with a Ph.D. in Pharmacology and Toxicology from the University of Otago, New Zealand.
- Babaji has experience in small molecules, combination products, and biologicals including vaccines, proteins, monoclonal antibodies, and advanced cell and gene therapies.
- Novotech has recently acquired EastHORN a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent.
- The acquisition is part of Novotech’s global expansion program in Europe and the US.